Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report) was the target of a large drop in short interest during the month of August. As of August 31st, there was short interest totaling 1 shares, a drop of 99.0% from the August 15th total of 101 shares. Based on an average daily trading volume, of 769 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are sold short.
Starpharma Price Performance
Starpharma stock opened at $5.05 on Friday. Starpharma has a fifty-two week low of $0.74 and a fifty-two week high of $5.82. The firm has a fifty day moving average price of $5.00 and a two-hundred day moving average price of $4.51.
Starpharma Company Profile
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
See Also
- Five stocks we like better than Starpharma
- MarketBeat Week in Review – 09/07 – 09/11
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
